Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Adaptimmune
Adaptimmune
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Yahoo Finance
ESMO
Adaptimmune
clinical trials
ADP-A2M4CD8
ovarian cancer
head and neck cancer
urothelial cancer
Flag link:
Adaptimmune says it's (nearly) ready to head to the FDA with TCR cancer therapy
Adaptimmune says it's (nearly) ready to head to the FDA with TCR cancer therapy
Endpoints
Adaptimmune
ASCO 2021
TCR therapeutics
Flag link:
ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas
ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas
Fierce Biotech
Adaptimmune
ASCO 2021
sarcomas
soft tissue sarcomas
clinical trials
Flag link:
Second-quarter catalysts for the smaller players
Second-quarter catalysts for the smaller players
EP Vantage
AC Immune
Anavex
Santhera
IMMUTEP
Syndax
Novan
Fulcrum Therapeutics
BeyondSpring
Corbus
Orphazyme
Aldeyra
Adaptimmune
Inflarx
Sutro
Gemini Therapeutics
Flag link:
Asco 2020 movers – cell therapy companies dominate the risers
Asco 2020 movers – cell therapy companies dominate the risers
EP Vantage
ASCO 2020
cell therapy
Adaptimmune
Allogene
Iovance
Flag link:
Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential
Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential
MedCity News
Adaptimmune
ASCO 2020
cell therapy
sarcoma
ADP-A2M4
Flag link:
Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies
Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies
BioSpace
Adaptimmune
SPEAR-T
Astellas
CAR-T
cell therapy
drug development
Flag link:
Struggling Adaptimmune gets a boost from the FDA as T-cell cancer drug wins an inside track at the agency
Struggling Adaptimmune gets a boost from the FDA as T-cell cancer drug wins an inside track at the agency
Endpoints
Adaptimmune
FDA
regenerative medicine
RMAT
ADP-A2M4
Flag link:
Q&A: Adaptimmune’s Elliot Norry on cell therapy
Q&A: Adaptimmune’s Elliot Norry on cell therapy
Pharmaforum
cell therapy
cancer
Adaptimmune
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Flag link:
Adaptimmune reports zero responses across three T cell therapy trials
Adaptimmune reports zero responses across three T cell therapy trials
BioCentury
Adaptimmune
t-cell therapies
clinical trials
Flag link:
Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study
Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study
CP Wire
Adaptimmune
MAGE-A4
solid tumors
Flag link:
Dose Escalation Cohort to be Initiated in Adaptimmune's MAGE-A4 SPEAR T-Cell Basket Study
Adaptimmune
MAGE-A4
Flag link:
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
CP Wire
Adaptimmune
GSK
GSK3377794
T-cells
Flag link:
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
Adaptimmune
GSK
GSK3377794
Flag link:
Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug
Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug
Endpoints
GSK
oncology
Adaptimmune
TCR therapeutics
Flag link:
After setback, Adaptimmune revamps T cell study
After setback, Adaptimmune revamps T cell study
BioPharma Dive
Adaptimmune
t cell therapy
NY-ESO SPEAR
ovarian cancer
Flag link:
Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now
Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now
Endpoints
Adaptimmune
T-cells
myxoid round cell liposarcoma
CAR-T
cancer immunotherapy
Flag link:
These 5 Biotech Stocks Under $10 Are About to Break Out
These 5 Biotech Stocks Under $10 Are About to Break Out
TheStreet.com
biotech
Ardelyx
Biocryst
Affimed
Adaptimmune
Sangamo BioSciences
Flag link:
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
Yahoo
Adaptimmune
GSK
immunotherapy
Flag link:
Pages
1
2
next ›
last »